The use of non-steroidal anti-inflammatory drugs in patients with arterial hypertension Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Dec 31, 2015
Keywords:
arterial hypertension, non-steroidal anti-inflammatory drugs

Main Article Content

Marcin Wełnicki
III Klinika Chorób Wewnętrznych i Kardiologii, II Wydział Lekarski, Warszawski Uniwersytet Medyczny

Abstract

Arterial hypertension is one of the most common cardiovascular risk factors. At the same time, population of hypertensive patients is in general very heterogenous as far as initial total cardiovascular risk is concerned. Non-steroidal anti-inflammatory drugs are one of the most frequently used drugs worldwide. Long-term use of these drugs increases total cardiovascular risk. In everyday practice, many patients with arterial hypertension are in need of non-steroidal anti-inflammatory drugs, both occasionally and in long-term. In this article, the author deals with potential side effects linked to such a use.

Downloads

Download data is not yet available.

Article Details

How to Cite
Wełnicki , M. (2015). The use of non-steroidal anti-inflammatory drugs in patients with arterial hypertension. Cardiology in Practice, 9(4), 17-21. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1317
Issue
Vol 9 No 4 (2015)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Tykarski A., Zdrojewski K., Gaciong Z.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego [www.nt.viamedica.pl] (dostęp 09.11.2015).
2. Mossakowska M., Więcek A., Błędowski P.: Aspekty medyczne, psychologiczne, socjologiczne i ekonomiczne starzenia się ludzi w Polsce. Wyd. 1. Termedia, Poznań 2012.
3. Jasik A., Tałała M.: Otyłość a choroba zwyrodnieniowa stawów. Postępy Nauk Medycznych 2013; XXVI, 5B: 14-18.
4. Grosser T., Fries S., FitzGerald G.A.: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006; 116: 4-15.
5. Abraham N.S., El-Serag H.B., Hartman C. et al.: Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment. Pharmacol. Ther. 2007; 25: 913-924.
6. Puszczewicz M.: Niesteroidowe leki przeciwzapalne. Przew. Lek. 2007; 3: 32-38.
7. Woroń J., Filipczak-Bryniarska I., Wordliczek J.: Nieopioidowe leki przeciwbólowe w farmakoterapii bólu. W: Malec-Milewska M., Woroń J. (red.): Kompedium leczenia bólu. Wyd 1. Medical Education, Warszawa 2012: 57-76.
8. Burke A., Smyth E., FitzGerald G.A.: Leki przeciwbólowe, przeciwgorączkowe; farmakoterapia dny moczanowej. W: Brunton L.L., Lazo J.S., Parker K.L. (red.): Farmakoterapia Goodmana & Gilmana. Wyd. 1. Czelej, Lublin 2007.
9. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur. Heart J. 2012; 33: 1635-1701.
10. Graham D.J.: COX-2 inhibitors, other NSAIDs, and cardiovascular risk – the seduction of common sense. JAMA 2006, Sep 12 [doi:10.1001/jama.296.13.jed60058].
11. Bresalier R.S., Sandler R.S., Quan H. et al.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005; 352: 1092-1102.
12. Bueno H., Bardají A., Patrignani P.: Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am. J. Cardiol. 2010; 105: 1102-1106.
13. McGettigan P., Henry D.: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296:1633-1644.
14. McGettigan P., Henry D.: Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011; 8(9): 1-18.
15. de Abajo F., Gil M., Poza P.: Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. Pharmacoepidemiol. Drug. Saf. 2014 [doi: 10.1002/pds].
16. Trelle S., Reichenbach S., Wandel S. et al.: Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
17. Varas-Lorenzo C., Riera-Guardia N., Calingaert B. et al.: Stroke risk and nonsteroidal anti-inflammatory drugs. A systematic review of observational studies. Pharmacoepidemiol. Drug. Saf. 2011; 20(12): 1225-1236.
18. Schjerning Olsen A.M., Fosbøl E.L., Lindhardsen J.: Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123(20): 2226-2235.
19. Friedewald V., Bennett J., Christo P.: AJC Editor’s consensus: selective and nonselective nonsteroidal anti-inflammatory drugs and cardiovascular risk. Am. J. Cardiol. 2010; 106: 873-884.
20. Sudano I., Flammer A.J., Périat D.: Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010; 122(18): 1789-1796.
21. Wilson S.L., Poulter N.R.: The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J. Hypertens. 2006; 24(8): 1457-1469.